Pricey or priceless : cost-effectiveness of respiratory syncytial virus (RSV) prevention in infants
Source
The Lancet regional health. Americas - ISSN 2667-193X-29 (2024) p. 1-2
COVID-19-related health utility values and changes in COVID-19 patients and the general population : a scoping review
Source
Quality of life research - ISSN 0962-9343-33:6 (2024) p. 1443-1454
Report of the WHO technical consultation on the evaluation of respiratory syncytial virus prevention cost effectiveness in low- and middle-income countries, April 7-8, 2022
Source
Vaccine - ISSN 0264-410X-41:48 (2023) p. 7047-7059
The age profile of respiratory syncytial virus burden in preschool children of low- and middle-income countries : a semi-parametric, meta-regression approach
Source
PLoS medicine - ISSN 1549-1277-20:7 (2023) p. 1-25
Economic burden and health-related quality-of-life among infants with respiratory syncytial virus infection : a multi-country prospective cohort study in Europe
Source
Vaccine - ISSN 0264-410X-41:16 (2023) p. 2707-2715